Has Pooja Rao, MD received payments from drug or device companies?

Yes. Drug and device makers reported $837 in general payments to Pooja Rao, MD across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pooja Rao, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pooja Rao, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pooja Rao, MD

Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1013352376

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 34.0% of the total. 2025 is the largest year on record at $478, 2.1 times the $227 reported in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.

$837in general payments, 2019–2025

Across 22 payments — averaging $38.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$284
Abbott$145
Teva Pharmaceuticals USA, Inc.$137
Insulet Corporation$107
AbbVie$77
Mannkind Corporation$43
plus $43 from 2 others

What the payments were for

Food & beverage$79495%
Education$435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	4	$284
Abbott	3	$145
Teva Pharmaceuticals USA, Inc.	6	$137
Insulet Corporation	2	$107
AbbVie	4	$77
Mannkind Corporation	1	$43
Sanofi-aventis U.S. LLC	1	$25
Sequel Med Tech, LLC	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SIMPLERA SENSOR$155
FREESTYLE LIBRE 3$125
MINIMED 780G$110

How this compares

$837 in reported general payments places this provider in the 30th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$41,755

Medicare patients

217

Services billed

594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	163	$162,156
MounjaroTirzepatide	60	$84,313
TrulicityDulaglutide	35	$43,809
FarxigaDapagliflozin Propanediol	37	$35,906
Soliqua 100-33Insulin Glargine/Lixisenatide	25	$32,825
Fiasp FlextouchInsulin Aspart (Niacinamide)	22	$30,095
JardianceEmpagliflozin	27	$28,765
Tresiba Flextouch U-100Insulin Degludec	35	$23,227
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	23	$22,546
Humulin R U-500 KwikpenInsulin Regular, Human	14	$21,444
Tresiba Flextouch U-200Insulin Degludec	16	$19,226
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	13	$13,384
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	13	$13,030
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	21	$10,121
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	64	$9,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33	$25	$32,82525 claims
AbbVieSynthroid	$77	$1,56626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

Other endocrinology, diabetes & metabolism in Tulsa

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →